SLIDESHOW: Showcasing Melanoma Research at the 56th Annual ACMS Meeting

References

1. Badin D, Salem I, Feng J, et al.Analyzing rate of recurrences and new primary melanotic malignancies post melanoma in situ diagnosis: findings from a single-center study. Poster presented at: 56th Annual ACMS Meeting. May 2-5, 2024; Phoenix, AZ.
2. Juhasz M, Gharavi N. Cutaneous melanoma upstaging during Mohs micrographic surgery. Poster presented at: 56th Annual ACMS Meeting. May 2-5, 2024; Phoenix, AZ.
3. Read C, Armstrong A. Factors that impact patients’ satisfaction with their dermatological surgeons: a population study among u.s. adults with melanoma and non-melanoma cutaneous cancers who underwent a surgical procedure. Poster presented at: 56th Annual ACMS Meeting. May 2-5, 2024; Phoenix, AZ.
4. Moody B, Sudhaman S, Ferguson J, et al. Feasibility of using a tumor-informed circulating tumor DNA (ctDNA) test for clinical decision-making in patients with resectable stage II/III melanoma. Poster presented at: 56th Annual ACMS Meeting. May 2-5, 2024; Phoenix, AZ.
5. Asamoah E, Demer A, Vidal N, et al. Immunohistochemistry-assisted Mohs surgery for treatment of invasive eyelid and periorbital cutaneous melanoma: oncologic and reconstructive outcomes. Poster presented at: 56th Annual ACMS Meeting. May 2-5, 2024; Phoenix, AZ.
6. DaCunha M, Coldiron B, Tassavor M, Bland M. Improving melanoma reporting adherence: the melanoma reporting model. Poster presented at: 56th Annual ACMS Meeting. May 2-5, 2024; Phoenix, AZ.
7. Campbell E, Reinhart J, Proffer S, et al. Incidence and mortality trends of primary cutaneous melanoma: a 50-year population-based study. Poster presented at: 56th Annual ACMS Meeting. May 2-5, 2024; Phoenix, AZ.
8. Freeman S, Carr D, Shahwan K, Latour E, Leitenberger J. Margin assessment in Mohs for melanoma: evaluation of interrater and intrarater reliability. Poster presented at: 56th Annual ACMS Meeting. May 2-5, 2024; Phoenix, AZ.